Reuters logo
BRIEF-Gensight Biologics reports long-term positive safety and visual acuity results in phase I/II GS010 study
June 14, 2017 / 5:37 AM / 5 months ago

BRIEF-Gensight Biologics reports long-term positive safety and visual acuity results in phase I/II GS010 study

June 14 (Reuters) - GENSIGHT BIOLOGICS SA

* GENSIGHT BIOLOGICS REPORTS LONG-TERM POSITIVE SAFETY AND VISUAL ACUITY RESULTS AT WEEK 96 IN PHASE I/II STUDY OF GS010 FOR THE TREATMENT OF LEBER’S HEREDITARY OPTIC NEUROPATHY (LHON)

* ‍CONFIRMATION OF LONG-TERM SAFETY PROFILE OF GS010​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below